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Abstract
Background Muscle wasting, anorexia, and metabolic dysregulation are common side-effects of cytotoxic chemotherapy,
having a dose-limiting effect on treatment efﬁcacy, and compromising quality of life and mortality. Extracts of Cannabis sativa,
and analogues of the major phytocannabinoid Δ9-tetrahydrocannabinol, have been used to ameliorate chemotherapy-induced
appetite loss and nausea for decades. However, psychoactive side-effects limit their clinical utility, and they have little efﬁcacy
against weight loss. We recently established that the non-psychoactive phytocannabinoid cannabigerol (CBG) stimulates appe-
tite in healthy rats, without neuromotor side-effects. The present study assessed whether CBG attenuates anorexia and/or
other cachectic effects induced by the broad-spectrum chemotherapy agent cisplatin.
Methods An acute cachectic phenotype was induced in adult male Lister-hooded rats by 6 mg/kg (i.p.) cisplatin. In total 66
rats were randomly allocated to groups receiving vehicle only, cisplatin only, or cisplatin and 60 or 120 mg/kg CBG (po, b.i.d.).
Feeding behavior, bodyweight and locomotor activity were recorded for 72 hours, at which point rats were sacriﬁced for post-
mortem analyses. Myoﬁbre atrophy, protein synthesis and autophagy dysregulation were assessed in skeletal muscle, plasma
metabolic proﬁles were obtained by untargeted 1H-NMR metabonomics, and levels of endocannabinoid-like lipoamines quan-
tiﬁed in plasma and hypothalami by targeted HPLC-MS/MS lipidomics.
Results CBG (120 mg/kg) modestly increased food intake, predominantly at 36-60hrs (p<0.05), and robustly attenuated cis-
platin-induced weight loss from 6.3% to 2.6% at 72hrs (p<0.01). Cisplatin-induced skeletal muscle atrophy was associated with
elevated plasma corticosterone (3.7 vs 13.1ng/ml, p<0.01), observed selectively in MHC type IIx (p<0.05) and IIb (p<0.0005)
ﬁbres, and was reversed by pharmacological rescue of dysregulated Akt/S6-mediated protein synthesis and autophagy pro-
cesses. Plasma metabonomic analysis revealed cisplatin administration produced a wide-ranging aberrant metabolic pheno-
type (Q2Ŷ=0.5380, p=0.001), involving alterations to glucose, amino acid, choline and lipid metabolism, citrate cycle, gut
microbiome function, and nephrotoxicity, which were partially normalized by CBG treatment (Q2Ŷ=0.2345, p=0.01). Lipidomic
analysis of hypothalami and plasma revealed extensive cisplatin-induced dysregulation of central and peripheral lipoamines
(29/79 and 11/26 screened, respectively), including reversible elevations in systemic N-acyl glycine concentrations which were
negatively associated with the anti-cachectic effects of CBG treatment.
Conclusions Endocannabinoid-like lipoamines may have hitherto unrecognized roles in the metabolic side-effects associated
with chemotherapy, with the N-acyl glycine subfamily in particular identiﬁed as a potential therapeutic target and/or bio-
marker of anabolic interventions. CBG-based treatments may represent a novel therapeutic option for chemotherapy-induced
cachexia, warranting investigation in tumour-bearing cachexia models.
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Introduction
Cachexia is a multi-factorial wasting syndrome, character-
ized by skeletal muscle atrophy, anorexia, and dysregulation
of metabolic homeostasis. The syndrome presents as a co-
morbidity with many common pathologies including chronic
heart failure and kidney disease, chronic obstructive pulmo-
nary disease, and most commonly cancer, with prevalence
of 50–80% in advanced cancer patients, of which 20% will
die as a result.1,2 While several decades of research have
helped elucidate the pathophysiology of the cancer-induced
cachexia syndrome, less appreciated is the contributory role
of cytotoxic chemotherapy regimens. In addition to the
well-documented side effects of anorexia and
chemotherapy-induced nausea and vomiting (CINV), evi-
dence is emerging for comorbidities that are closely related
to cancer-induced cachexia, characterized by muscle atro-
phy and metabolic dysregulation that is qualitatively distinct
from nausea and starvation-induced pathophysiology.3–8
This syndrome, which we and others describe as chemo-
therapy-induced cachexia,9 is highly debilitating to patients,
has a dose-limiting effect on treatment efﬁcacy, and com-
promises quality of life and ultimately mortality. Despite a
considerable translational research effort and numerous
clinical trials, to date no speciﬁc treatments for cancer-
induced cachexia are currently licensed,10 and strategies
to ameliorate the side effects of chemotherapy are limited
to anti-emetics and control of acute nausea.11
Pharmacological interventions based on Cannabis sativa
have been utilized clinically for decades to prevent CINV
and anorexia associated with AIDS and cancer, with
dronabinol, a synthetic form of Δ9-tetrahydrocannabinol
(Δ9-THC), licensed for CINV in 1985.12–14 Coupled with the
well-documented hyperphagic effects of Δ9-THC, this led to
clinical trials of C. sativa extracts, puriﬁed Δ9-THC, and
dronabinol against cancer-induced cachexia. However, these
failed to demonstrate efﬁcacy, in part due to dose-limiting
psychoactive side effects.15,16 In addition to Δ9-THC, there
are now known to be over 100 other phytocannabinoids in
C. sativa, the majority of which are non-psychoactive, some
of which have appetite-modulating effects.17–20 We have re-
cently shown that cannabigerol (CBG), a non-psychoactive
phytocannabinoid, increases food intake in healthy rats with-
out eliciting neuromotor side effects.21,22 Given that patients
undergoing chemotherapy commonly report appetite loss, al-
tered food palatability, and early satiety,23–26 CBG may have
potential to attenuate these anorectic side effects. While
the molecular targets of CBG are poorly characterized, it
has been shown to be an agonist at PPARγ and inhibitor of
anandamide cellular uptake at micromolar concentra-
tions,27,28 which are achieved in brain and plasma following
oral administration of CBG at doses used in our studies to
elicit hyperphagia.29 These pharmacological activities of CBG
could conceivably mediate beneﬁcial effects in the context
of cachexia on appetite, inﬂammation, and multiple aspects
of metabolic function.30–32
The present study was designed to test the hypothesis
that CBG is able to attenuate the anorexia, weight loss,
and metabolic dysregulation induced by the broad-
spectrum cytotoxic chemotherapy agent cisplatin. We uti-
lized a previously validated rat model of cisplatin-induced
cachexia, in which an acute cisplatin dose induces progres-
sive bodyweight loss and anorexia, which reaches a nadir
48–72 h after administration.33–35 Animals were randomly
allocated to receive either saline and vehicle (CON), cis-
platin and vehicle (CIS), or cisplatin and CBG at 60 or
120 mg/kg b.i.d. (CIS + CBG60 and CIS + CBG120). Food in-
take, bodyweight, and locomotor activity were recorded
over 72 h, after which animals were sacriﬁced, and plasma,
hypothalamus, and muscle samples were taken for ex vivo
analyses. Muscle mass and molecular markers of protein
synthesis and catabolic pathways were assessed by immu-
nohistochemistry and Western blot to investigate effects
of CBG on cisplatin-induced muscle atrophy. Given the
multi-factorial nature of cachexia, and the pleiotropic activ-
ity proﬁles typical of phytocannabinoids, metabonomic and
lipidomic proﬁles were obtained from plasma and hypothal-
amus samples to further characterize the pathophysiology
of cisplatin-induced metabolic dysregulation and any
normalization due to CBG treatment. These multi-omic
datasets were interrogated to identify the salient compart-
ments and biochemical processes associated with the ther-
apeutic effects of CBG.
Materials and methods
Study design
The controlled laboratory experiment reported here was
conducted to test the pre-speciﬁed hypothesis that the
appetite-stimulating phytocannabinoid CBG would attenuate
the anorexia and/or weight loss induced by a single
6 mg/kg dose of cisplatin in rats. Primary endpoints were
cumulative food intake, bodyweight change, and muscle
mass at the end of the 72 h test, a duration speciﬁed
based on literature reports that this timepoint represents
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the nadir of cisplatin’s cachectic effects.23,33–35 Animals were
randomized to one of four groups as detailed below, with
sample sizes based on literature reports of this model and
our own pilot studies. Additional in vitro analyses were
conducted as detailed below, using post-mortem tissue
samples to investigate the effects of cisplatin, and CBG
treatment, on muscle catabolism, plasma metabolic and
hypothalamic and plasma lipidomic phenotypes. All post-
mortem analyses were conducted by experimenters blinded
to treatment.
Animals
Male Lister hooded rats (Harlan, UK) weighing 200–225 g at
the start of studies were housed in pairs in the test room
on a 12/12 light cycle (white light on at 11:00) with standard
laboratory chow and water available ad libitum. Animals were
habituated to the test environment and handling for 7 days
prior to the start of testing. Sixty-six animals were tested in
total, nine of which were excluded as asymptomatic for the
cachectic effects of cisplatin (as detailed below) and a further
Figure 1 Cannabigerol attenuates cisplatin-induced weight loss, anorexia, and myoﬁbre hypotrophy. Experimental timeline and dosing schedule (A),
bodyweight change (B, C), and cumulative food intake (D, E) prior to post-mortem tissue harvest 72 h after administration of 6 mg/kg cisplatin. Data
presented as mean ± SEM and analysed by two-way mixed-model ANOVA (drug × day) followed by one-way between-subjects ANOVA and Tukey’s post
hoc comparisons at each timepoint, n = 11–16.
###
P < 0.0005 vs. CON,
*
P < 0.05 vs. CIS,
**
P < 0.01 vs. CIS. Mass of isolated extensor digitorum longus
(EDL) muscle 72 h after cisplatin administration (F; n = 11–15) and cross-sectional area (CSA) of myoﬁbres by MHC ﬁbre type (G; n = 7–10). Data pre-
sented as mean ± SEM and analysed by one-way between-subjects ANOVA and planned comparisons. *P < 0.05, ***P < 0.0005.
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two excluded due to technical errors with the automated
food intake system. All animal protocols were approved by
the University of Reading and followed ARRIVE guidelines.
Drugs
Cisplatin (cis-diammineplatinum (II) dichloride; Sigma-Aldrich,
UK) was dissolved by sonication in sterile 0.9% saline at
1.5 mg/mL and administered intraperitoneally at a volume
of 4mL/kg, at the onset of the light period (11:00) on the ﬁrst
day of testing. CBG (GW Research Ltd, UK) was dissolved in
sesame seed oil (by magnetic stirring at 57°C) at 120 mg/mL
and administered per ora at 60 or 120 mg/kg in 1 mL/kg dose
volume. Animals were administered CBG or vehicle immedi-
ately prior to cisplatin, then subsequently every 12 h at the
light/dark period transition throughout the 3 day test session
(Figure 1A).
In vivo protocol
The protocol for induction of cisplatin-induced anorexia and
fatigue was based on previously published studies using a sin-
gle dose of cisplatin at 6 mg/kg.33–35 Brieﬂy, following 1 week
of habituation to handling, animals were weighed and admin-
istered sesame oil vehicle at light onset (11:00) and immedi-
ately placed in test chambers for 24 h for a habituation and
baseline session. Animals were then randomly allocated to re-
ceive saline and sesame oil vehicles (CON), cisplatin and ses-
ame oil vehicle (CIS), cisplatin and 60 mg/kg CBG (CIS + CBG
60), or cisplatin and 120 mg/kg CBG (CIS + CBG 120). Success-
ful randomization was conﬁrmed by a lack of signiﬁcant over-
all analysis of variance (ANOVA) results for measures of
bodyweight, 24 h food intake, or 24 h locomotor activity dur-
ing baseline sessions (Supporting Information, Table S1). Af-
ter 24 h in home cages following baseline sessions, animals
began a 72 h test session at 11:00. Animals were adminis-
tered an initial dose of CBG or vehicle, immediately prior to
cisplatin or saline, and placed in test cages, then subse-
quently dosed with CBG or vehicle every 12 h for the remain-
der of the test. Health checks and bodyweight measurements
were conducted every 12 h immediately before dosing. Food
intake and locomotor activity were recorded automatically as
previously described,21,22,36 with video recordings used to
conﬁrm feeding episodes. At the end of the 72 h test period,
animals were euthanized by CO2 inhalation, blood samples
collected by cardiac puncture, and hypothalami rapidly re-
moved and snap frozen on liquid nitrogen. Extensor
digitorum longus (EDL) muscles were removed from both
hind limbs, weighed, and snap frozen.
Data processing and analysis
Pilot studies using this model revealed a considerable hetero-
geneity in cachectic response to cisplatin, with a discrete
minority of animals displaying little or no discernible effect
on bodyweight or food intake. Using pilot data, a priori exclu-
sion criteria were determined and applied prospectively to
the present study, resulting in the exclusion of nine animals
as effectively asymptomatic for the cachectic effects of cis-
platin (across the three groups administered cisplatin). Ani-
mals were excluded if they failed to show a minimum
cachectic response of either <9 g food intake during the ﬁrst
dark period (12–24 h) or a loss of >3% bodyweight at 36 h
(Supporting Information, Figure S2). These criteria, which
were 2 SD below the mean intake and bodyweight measures
of saline-treated controls in our pilot experiments, ensured
CBG efﬁcacy was only assessed in animals showing a robust
cisplatin-induced cachectic effect consistent with previous
studies. Data were analysed using two-way mixed-model
ANOVA (drug × time) and/or one-way ANOVA (drug),
followed by Tukey’s all-pairwise comparisons for main out-
come dose–response measures, or planned comparisons
(CON vs. CIS and CIS vs. CIS + CBG 120) for port-mortem anal-
yses, as detailed in ﬁgure legends. Where assumptions of
sphericity were violated (as indicated by a signiﬁcant
Mauchly’s test result), degrees of freedom and P values from
the Greenhouse–Geisser correction were utilized. Results
were considered signiﬁcant at α = 0.05.
Ex vivo analysis of muscle atrophy
Post-mortem analyses of muscle ﬁbre atrophy, and molecular
markers of anabolic and catabolic signalling pathways in mus-
cle tissue, were conducted by immunohistochemistry and
Western blot, as fully detailed in the Supporting Information.
Corticosterone and cytokine analyses
Post-mortem plasma samples were used in commercial ELISA
kits to quantify concentrations of corticosterone (Enzo Life Sci-
ences, Exeter, UK), IL-1β (Abcam, Cambridge, UK), IL-6 (Novex,
Thermoﬁsher, Waltham, MA), and TNFα (Thermoﬁsher, Wal-
tham, MA) according to manufacturers’ instructions.
1H-NMR spectroscopy-based metabonomics
analysis
An untargeted 1H-NMR spectroscopy-based metabonomics
approach was used to determine the plasma metabolic pro-
ﬁles of animals in CON, CIS, and CIS + CBG120 groups 72 h af-
ter cisplatin administration. Multivariate modelling including
principal component analysis (PCA) and orthogonal projection
to latent structures discriminant analysis (OPLS-DA) were per-
formed using in-house scripts and those provided by Korrigan
Sciences Ltd, UK. Sample preparation, spectra acquisition,
and data processing were conducted as previously reported37
and detailed in the Supporting Information.
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HPLC–MS/MS lipidomic analysis of
endocannabinoids and lipoamines
Targeted HPLC–MS/MS lipidomic analysis was performed on
hypothalamus and plasma samples from animals in CON,
CIS, and CIS + CBG120 groups, harvested 72 h after cisplatin
administration, as previous reported38 and fully detailed in
the Supporting Information. Hypothalamus samples were
screened against a library of 71 lipoamines (including ananda-
mide), four 2-acyl-sn-glycerols (including 2-AG), arachidonic
and linoleic acids, and the prostaglandins PGE2 and PGF2α.
Plasma samples were screened for 18 of the lipoamines
(known to be detectable in plasma), in addition to the 2-
acyl-sn-glycerols, free fatty acids, and prostaglandins.
Results
Cannabigerol attenuates cisplatin-induced weight
loss, anorexia, and myoﬁbre hypotrophy
Consistent with previous reports using this model of
chemotherapy-induced cachexia, administration of cisplatin
resulted in progressive loss of bodyweight over the 72 h test
(Figure 1B,C; drug × time F7.3, 124.3 = 14.731, P < 0.0005). An-
imals administered cisplatin alone lost 6.3% bodyweight after
72 h (P < 0.0005), consistent with the clinical diagnostic
criteria for cachexia of ≥5% bodyweight loss.39 While treat-
ment with 60 mg/kg CBG did not have a signiﬁcant protective
effect against this loss, 120 mg/kg CBG signiﬁcantly attenu-
ated bodyweight loss at all timepoints. At 24 h, 120 mg/kg
CBG reduced cisplatin-induced weight loss by approximately
half (P = 0.006), and effectively prevented any further de-
crease during the remaining test duration, such that this
group only lost 2.6% after 72 h (P = 0.004). Cisplatin elicited
a profound anorectic effect (Figure 1D,E; drug × time F3.4,
57.0 = 26.648, P < 0.0005), apparent from 24 h onwards, with
cumulative intake at 72 h of 34 g compared with 67 g in con-
trols (P < 0.0005). This anorectic effect was due to decreased
feeding frequency during animals’ active (dark) phase on days
1–3, and reductions in meal size on days 2–3 (Supporting In-
formation, Table S2). Treatment with 120 mg/kg CBG elicited
a mild hyperphagic response during the ﬁrst 12 h and a signif-
icant protective effect against cisplatin-induced anorexia
from 36–60 h (P = 0.018, P = 0.045, and P = 0.044, respec-
tively; Figure 1D), with a near-signiﬁcant increased total in-
take over the test duration (P = 0.067). Cisplatin-induced
reductions in meal size were prevented by 120 mg/kg CBG
during the dark phase of day 3 (P = 0.037). Cisplatin also in-
duced a suppression of dark phase ambulatory locomotor ac-
tivity on days 1–3, which was not signiﬁcantly altered by
either dose of CBG (Supporting Information, Table S3).
To investigate the extent to which cisplatin-induced weight
loss was driven by skeletal muscle atrophy, hindlimb muscle
mass and myoﬁbre hypotrophy were quantiﬁed in post-
mortem samples from CON, CIS, and CIS + CBG120 animals
taken at the nadir of cisplatin’s cachectic effects (72 h).
Drug-induced alterations in the mass of EDL muscle were
observed (Figure 1F; F2, 36 = 10.146, P < 0.0005), which
was reduced by 6.7% by cisplatin (P < 0.0005). However,
CBG attenuated this loss to 3.2% (P = 0.021). Immunohisto-
chemical analysis of myoﬁbre hypotrophy by MHC ﬁbre type
(Figure 1G) demonstrated cisplatin-induced reductions of
cross-sectional area in fast glycolytic type IIx (P = 0.025) and
IIb (P < 0.0005) ﬁbres, which were attenuated by CBG treat-
ment (P = 0.018 and P = 0.025). In contrast, no cisplatin-
induced hypotrophy was observed in slow oxidative type Ia
or fast oxidative/glycolytic type IIa ﬁbres.
Cannabigerol rescues cisplatin-induced
dysregulation of myoﬁbre autophagy and protein
synthesis
Inﬂammation-mediated HPA axis activation, and subsequent
chronic elevation of systemic corticosterone, has recently
been demonstrated to induce myoﬁbre atrophy following
cyclophosphamide-doxorubicin-5-ﬂuorouracil chemotherapy
in mice.5 Given that corticosterone-induced atrophy selec-
tively occurs in MHC IIb/x ﬁbres,40,41 resulting from dysregu-
lated autophagy-lysosome catabolism and inhibited muscle
protein synthesis,42we investigated these pathways in plasma
and EDL muscle samples from animals administered cisplatin
and treated with 120 mg/kg CBG. Plasma corticosterone con-
centration was increased by cisplatin 72 h after administra-
tion; however, this was not modulated by CBG treatment
(Figure 2A; P = 0.002 and P = 0.754). In contrast, plasma con-
centrations of the pro-inﬂammatory cytokines IL-1β, IL-6,
and TNFα were below the limit of quantitation or unaffected
by either cisplatin or CBG at this timepoint (data not shown).
Dysregulation of autophagic ﬂux, a mechanism of muscle
catabolism recently implicated in cachexia,43,44 was inves-
tigated by Western blot for the ratio of active LC3 protein
(LC3 II) to the inactive cleaved form of the propeptide (LC3 I;
Figure 2B and Supporting Information, Figure S3), expres-
sion of p62 protein (Figure 2C and Supporting Information,
Figure S3), and by immunohistochemical analysis of p62 + ve
puncta density in myoﬁbres (Figure 2D,E). Cisplatin elicited a
near-signiﬁcant reduction in active LC3 ratio (P = 0.073), which
was increased by CBG treatment (P < 0.0005). Expression of
p62 was reduced by cisplatin (P = 0.002) and partially normal-
ized by CBG treatment (P = 0.051). These results imply that au-
tophagy is blunted by cisplatin but is activated by CBG. We
investigated this further by quantifying p62 puncta that accu-
mulate when autophagy is blunted. Consistent with the notion
of blunted autophagy, cisplatin induced a signiﬁcant increase
in p62 + ve puncta density (P = 0.0029), which was normalized
to control levels by CBG treatment (P = 0.004).
Chemotherapy-induced cachexia isattenuated by cannabigerol 5
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12426
We next proﬁled key components of the protein synthesis
pathway to develop a mechanistic understanding of the
changes in muscle mass induced by cisplatin and CBG by pro-
ﬁling Akt and SGK-1, as well as key downstream targets (Figure
2F–J and Supporting Information, Figure S3). Cisplatin elicited
a near-signiﬁcant reduction in pAkt ser473 (P = 0.088), while
CBG signiﬁcantly increased this ratio above control levels
(P < 0.0005). Phosphorylation of Akt at the thr308 residue
was reduced four-fold by cisplatin (P < 0.0005), which was
normalized to near control levels by CBG (P < 0.0005). Phos-
phorylation of ribosomal protein S6 (the downstream target
of Akt) was reduced six-fold by cisplatin (P< 0.0005), and this
reduction was normalized to control levels by CBG
(P < 0.0005). In addition to the effects on the canonical
Akt/S6 protein synthesis pathway, cisplatin also decreased
the number of SGK1 + ve ﬁbres in EDL muscle (P = 0.025); how-
ever, this was not signiﬁcantly altered by CBG treatment
(P = 0.358). These results demonstrate that suppression of
normal anabolic protein synthesis contributes to cisplatin-
induced muscle atrophy and that this suppression is normal-
ized by CBG treatment, primarily via the Akt-S6 pathway.
Cannabigerol partially normalizes the
cisplatin-induced aberrant metabolic phenotype
HPLC and 1H-NMR spectroscopy-based metabonomic ap-
proaches have recently been used to investigate markers of
metabolic abnormalities in urine and kidney associated with
cisplatin-induced nephrotoxicity.45,46 Here, we report the
use of untargeted 1H-NMR spectroscopy-based metabo-
nomics to characterize the systemic metabolic disruptions in-
duced by a cachectic dose of cisplatin and to identify
metabolic processes involved in the anti-cachectic effects of
Figure 2 Cannabigerol rescues cisplatin-induced dysregulation of myoﬁbre autophagy and protein synthesis. Plasma corticosterone levels deter-
mined by ELISA (A; n = 6–9); EDL muscle tissue Western blot analysis of autophagy markers LC3 (B) and p62 (C) and immunohistochemical quantiﬁca-
tion of p62 (D, E; scale bars = 100 μm); expression of protein synthesis markers pAkt ser473 (F), pAkt thr308 (G) and pS6 (H) and immunohistochemical
quantiﬁcation of protein synthesis marker SGK1 (I, J; scale bars = 100 μm; all n = 3). Data presented as mean ± SEM and analysed by one-way between-
subjects ANOVA and planned comparisons. *P < 0.05, **P < 0.01, ***P < 0.0005.
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Figure 3 Cannabigerol partially normalizes the cisplatin-induced aberrant metabolic phenotype. Principal component analysis scores plots (PC1 vs.
PC2/3, % variance in parentheses) of the 1H-NMR plasma metabolic proﬁles for pairwise comparisons of CON vs. CIS (A), CIS vs. CIS + CBG120 (B), and
CON vs. CIS + CBG120 (C). Orthogonal projection to latent structures discriminant analysis (OPLS-DA) revealed a widespread aberrant metabolic phe-
notype induced by cisplatin (D; Q
2Ŷ = 0.5380, P = 0.001), with many of these cisplatin-induced metabolite changes partially reversed by CBG treatment
(E; Q2Ŷ = 0.2345, P = 0.01). Relative abundance plots for all individual metabolites derived from the OPLS-DA integrals are provided in Supporting In-
formation, Figure S4.
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CBG. Biochemical proﬁles were acquired from the post-
mortem plasma samples of animals in CON, CIS, and
CIS + CBG120 groups. PCA was used to identify metabolic var-
iation in the plasma proﬁles associated with cisplatin and/or
CBG treatment. From the pairwise PCA model, clear meta-
bolic variation was observed between the CON and CIS pro-
ﬁles (Figure 3A). This is consistent with the widespread
metabolic dysregulation that characterizes the cachectic phe-
notype. The pairwise PCA model comparing the plasma met-
abolic proﬁles from CIS and CIS + CBG120 groups showed a
modest degree of overlap between the groups (Figure 3B), al-
though the overall distributions were distinct. Interestingly, a
greater spread was observed in the CIS + CBG120 proﬁles in-
dicating a heterogeneous response to CBG treatment, consis-
tent with the effects on main outcome measures seen in vivo.
No distinct clustering was observed in the scores plot from
the PCA model comparing the CON and CIS + CBG120 proﬁles
(Figure 3C), suggesting these groups exhibit much greater ho-
mogeneity, reﬂecting a normalization of the cisplatin-
associated metabolic variation by CBG treatment.
To identify individual metabolites driving the cisplatin-
induced alterations to metabolic phenotype, and those nor-
malized by CBG treatment, OPLS-DAwas applied to these met-
abolic proﬁles (Figure 3D,E and Supporting Information, Figure
S2; CON vs. CIS: Q2Ŷ = 0.5380, P = 0.001, CIS vs. CIS + CBG120:
Q2Ŷ = 0.2345, P = 0.01). The cisplatin-induced phenotype
(Figure 3D) was characterized by hyperglycaemia and elevated
creatinine, glycine, allantoin, the ketone body 3-hydroxy-
butyrate, and the marker of gut microbiome choline
metabolism dimethylamine. Relative to controls, cisplatin re-
duced creatine, citrate, the gut microbiome metabolite
trimethylamine-N-oxide (TMAO), the branched-chain amino
acids (BCAAs) leucine, isoleucine and valine, and choline deriv-
atives dimethylglycine and glycerophosphocholine. Pairwise
comparison of CIS + CBG120 and CIS samples (Figure 3E) con-
ﬁrmed the partial normalization of the aberrant metabolic
phenotype suggested by PCA analysis, with samples from the
CIS + CBG120 group having lower levels of glucose, creatinine,
allantoin, 3-hydroxybutyrate, and higher trimethylamine-N-
oxide and BCAAs, than those from the CIS group. No signiﬁ-
cant differences were observed between the CIS + CBG120
and CON proﬁles conﬁrming the attenuation of CIS-induced
biochemical perturbations by CBG treatment.
Cisplatin-induced cachexia is associated with
extensive modulation of hypothalamic and
systemic endocannabinoid and lipoamine signalling
While the molecular targets of CBG are quite poorly charac-
terized, it has known afﬁnities for several enzymes and recep-
tors involved in endocannabinoid signalling.27,28,47,48 The
canonical endocannabinoids, N-arachidonoyl ethanolamine
(AEA / anandamide) and 2-arachidonoyl glycerol (2-AG), and
an increasing number of the structurally analogous lipoamine
and 2-acyl-sn-glycerol signalling lipids, have established
modulatory roles in many metabolic processes dysregulated
in cachectic pathophysiology.49,50 Furthermore, recent
metabonomic studies of cisplatin toxicity have reported alter-
ations to pathways involved in amino acid and lipid metabo-
lism, involving the substrates for endocannabinoid and
lipoamine synthesis.46 We thus conducted targeted HPLC–
MS/MS lipidomic analyses of hypothalamus and plasma sam-
ples from animals administered cisplatin and CBG, to test the
hypotheses that cisplatin-induced cachexia is associated with
alterations to signalling lipids and that the anti-cachectic ef-
fects of CBG involve normalization of such signalling.
Of the 79 lipids screened in hypothalami (Supporting Infor-
mation, Table S4), cisplatin signiﬁcantly altered the concen-
trations of 29 lipoamines/2-acyl-sn-glycerols from 11
subfamilies, and 11 of the 26 lipids screened for in plasma
(Table 1 and Supporting Information, Table S5). Of particular
note are the 1.5-fold to three-fold decreases in all six hypo-
thalamic N-acyl ethanolamines (NAEs), including anandamide,
and similar decreases in plasma NAEs. Reductions were also
seen in hypothalamic concentrations of various N-acyl GABAs,
-leucines, -prolines, -serines, -taurines, and -valines. In con-
trast, concentrations of several different N-acyl phenylala-
nines and -tyrosines were increased by cisplatin, but 2-
acyl-sn-glycerols (including 2-AG), free fatty acids, and prosta-
glandins were unaffected. In hypothalami, CBG treatment
generally had a minimal effect on cisplatin-induced alter-
ations; however, increases in N-palmitoyl proline, N-stearoyl
proline, and N-stearoyl tyrosine were reversed. Plasma con-
centrations of linoleic and arachidonic acids were also in-
creased by cisplatin and unaffected by CBG treatment. At
the post-mortem time of sampling, these data suggest that
the anti-cachectic effects of CBG are not mediated by the
normalization of wider endocannabinoid-like lipid signalling
in central metabolic control regions. However, in contrast to
the modest CBG-induced alterations in the central lipidomic
proﬁle, plasma concentrations of the N-acyl glycine subfamily
exhibited a remarkably consistent association with the anti-
cachectic effects of CBG treatment (Table 1, Figure 4, and
Supporting Information, Figure S5). With the exception of
N-docosahexaenoyl glycine, concentrations of all lipoamines
in this subfamily were signiﬁcantly increased by cisplatin
(P < 0.05–0.001; Figure 4A–E), and CBG attenuated the in-
creases in N-palmitoyl glycine (P < 0.05), N-stearoyl glycine
(P < 0.01), and N-oleoyl glycine (P < 0.05).
Cannabigerol has a prohomeostatic effect on
systemic cachectic phenotype
Given the complex and diverse phenotypic alterations ob-
served in this model, cluster and correlational analyses were
performed on the metabonomic and lipidomic datasets to
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Table 1 Single-dose cisplatin administration extensively modulates hypothalamic anandamide and lipoamine concentrations. Targeted HPLC–MS/
MS lipidomic analysis was used to screen hypothalamic samples for 71 lipoamine and four 2-acyl-sn-glycerol lipoamines in addition to linoleic and ara-
chidonic acids and the prostaglandins PGE2 and PGF2α, with plasma samples screened for 18 of the lipoamine lipids, as detailed in Supporting Informa-
tion, Table S3.
Boxes in solid blue or red denote lipids signiﬁcantly increased or decreased, respectively, with shaded boxes denoting alterations that
were near signiﬁcance (P < 0.01). BLD, below limit of detection. Number of arrows indicates the magnitude of difference (one ar-
row = one-fold to 1.49-fold change; two arrows = 1.5-fold to 1.99-fold change; three arrows = two-fold to 2.99-fold change; four ar-
rows = three-fold to 9.99-fold change). The canonical endocannabinoids N-arachidonoyl ethanolamine (anandamide/AEA) and 2-
arachidonoyl-sn-glycerol (2-AG) are highlighted in bold. Only lipoamines for which at least one signiﬁcant comparison was observed
are presented here; concentrations of all lipoamines screened in hypothalamus and plasma samples are provided in Supporting Informa-
tion, Table S5. All data analysed by one-way between-subjects ANOVA and post hoc Fisher’s LSD tests where appropriate, n = 11–16.
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clarify the important compartments and pathways involved in
the prohomeostatic effect of CBG. Cluster analyses were used
to determine the similarity between CON, CIS, and CIS +
CBG120 groups at the levels of metabonomic phenotype
(Figure 5A), hypothalamic lipidomic phenotype (Figure 5B),
and the combined systemic phenotype (Figure 5C), comprising
all metabolites, plasma lipoamines, and primary outcome
measures of bodyweight, food intake, and EDL muscle mass.
Consistent with PCA and OPLS-DA analyses, cluster analysis
of the metabonomic phenotype demonstrated the greatest
similarity between CON and CIS + CBG120 groups, supporting
the notion that CBG treatment partially normalizes plasma
metabolic phenotype. In contrast, a substantial degree of
similarity was observed in the hypothalamic lipidomic pheno-
type between CIS and CIS + CBG120 groups, conﬁrming the
qualitative observation that CBG has little effect on cisplatin-
induced alterations to central lipoamines. Most notably, the
combined systemic phenotype of animals treated with CBG
wasmost similar to control animals, conﬁrming a wide-ranging
prohomeostatic effect of CBG treatment.
Correlational analyses were then conducted between all
individual plasma metabolites, plasma lipoamines/2-acyl-sn-
glycerols, and main outcome measures in each of CON, CIS,
and CIS + CBG120 groups (Figure 5D–F). Of note, the negative
correlation between plasma arachidonic acid and bodyweight
in control animals was lost in those administered cisplatin but
Figure 4 Cannabigerol attenuates cisplatin-induced increases in plasma N-acyl glycine concentrations. All data analysed by one-way between-sub-
jects ANOVA and post hoc Fisher’s LSD tests where appropriate, n = 11–16. *P < 0.05, **P < 0.01, ***P < 0.0005.
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re-established with CBG treatment. More strikingly, strong
negative correlations were observed in CBG-treated animals
between EDL muscle mass and plasma concentrations of
N-stearoyl glycine (r = 0.7477, R2 = 0.5591, P = 0.0033;
Supporting Information, Figure S5A), N-oleoyl glycine
(r = 0.6971, R2 = 0.486, P = 0.0081; Supporting Information,
Figure S5B), N-palmitoyl glycine (r = 0.6068, R2 = 0.3682,
P = 0.0279; Supporting Information, Figure S5C), N-
arachidonoyl glycine (r = 0.6523, R2 = 0.4255, P = 0.0157;
Supporting Information, Figure S5D), and N-linoleoyl glycine
(r = 0.6203, R2 = 0.3848, P = 0.0237; Supporting Informa-
tion, Figure S5E). These data provide further evidence for
the association between systemic N-acyl glycine signalling
and the anti-cachectic effects of CBG treatment and suggest
that these lipoamines may represent novel biomarkers of an-
abolic treatment efﬁcacy.
Figure 5 Cannabigerol has a prohomeostatic effect on systemic cachectic phenotype. cluster analyses of metabolite and lipid concentrations be-
tween three treatment groups for metabonomic phenotype (A), hypothalamic lipidomic phenotype (B) and combined systemic phenotype comprising
all plasma metabolites, plasma lipoamines and main outcome measures of bodyweight, food intake, and EDL muscle mass (C). Dendrograms were pro-
duced using the single-linkage method and Euclidean distance measure. The similarity level at any step is the percentage of the minimum distance at
that step relative to the maximum inter-observation distance in the data. Correlograms of all signiﬁcant Spearman’s rho correlations between all in-
dividual metabolites, lipoamines and outcome measures comprising the combined systemic phenotype, for animals in CON (D), CIS (E), and
CIS + CBG120 (F) groups. Colour intensity and size of circles are proportional to correlation coefﬁcients.
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Discussion
The data presented here demonstrate that CBG (at
120mg/kg, b.i.d.) has protective effects against multiple com-
ponents of chemotherapy-induced cachexia pathophysiology,
including anorexia, weight loss, muscle atrophy, and meta-
bolic dysregulation. In addition, it provides the ﬁrst evidence
that cisplatin administration profoundly alters hypothalamic
and systemic levels of many endocannabinoid-like signalling
lipids and that the beneﬁcial effects of CBG in this model
are associated with modulation of the N-acyl glycine
lipoamine subfamily.
Cannabigerol produced a robust therapeutic effect on total
bodyweight change, with the magnitude of cisplatin-induced
weight loss reduced by approximately 60%. CBG exerted a
considerable protective effect within 24 h and prevented fur-
ther weight loss over the remaining experimental timecourse.
Previous studies in this model over a longer duration have
shown the effects of acute cisplatin on bodyweight reach a
nadir 48–72 h after administration, after which they slowly
return to near baseline levels after 16 days.23,33–35 The pres-
ent data thus strongly suggest that CBG is able to robustly
protect against the most detrimental phase of cisplatin-
induced weight loss. Somewhat in contrast to this robust
effect, CBG produced only a modest attenuation of
cisplatin-induced anorexia, predominantly during the 36–
60 h period. This cisplatin-induced anorexia was characterized
by decreases in feeding frequency and meal size, suggesting a
suppression of consummatory feeding processes, with CBG
signiﬁcantly increasing meal size during the third dark period
only. These observations suggest that the protective effect of
CBG against cisplatin-induced weight loss was not solely due
to attenuation of anorexia, and indeed appears to be largely
independent of its hyperphagic effects. This apparent
decoupling of the hyperphagic effects of CBG from its thera-
peutic effects against muscle catabolism further supports the
contention that cisplatin does indeed elicit a bona ﬁde
chemotherapy-induced cachectic pathophysiology—a syn-
drome more physiologically complex than simply starvation
due to nausea and vomiting. Segregation of the starvation-
induced components of the observed pathophysiology by
incorporation of a pair-fed group was beyond the scope of
the present study. However, similar analyses have recently
been conducted in mouse models of cisplatin-induced ca-
chexia, which reported marked differences in hindlimb
muscle mass, myoﬁbre hypotrophy, molecular markers for
muscle atrophy, and lipolysis and β-oxidation between
cisplatin and pair-fed (and water-restricted) groups.4,7
To investigate the putative anti-cachectic effect of CBG on
muscle homeostasis, a detailed investigation of these drugs’
effects on muscle catabolism mechanisms was conducted.
Cisplatin caused substantial loss of skeletal muscle mass after
72 h, due to selective atrophy of fast glycolytic type IIx and IIb
myoﬁbres consistent with hyperactivation of endogenous
glucocorticoid (GC) signalling,40,41,51 and indeed, the ﬁrst ob-
servations of cachexia-associated elevations in systemic corti-
costerone following cisplatin administration are reported
here. The failure to detect elevations in pro-inﬂammatory
cytokines is perhaps surprising, and may be due to the rela-
tively late timepoint at which plasma samples were obtained.
However, recent studies suggest that, in contrast to their
established role in the pathophysiology of cancer-induced ca-
chexia, they may not have such physiological relevance in the
chemotherapy-induced aspects of this syndrome.4,48 Further
evidence for a central role of hyperactivated GC signalling in
cisplatin-induced muscle catabolism, and the prohomeostatic
effects of CBG in this process, was obtained from the plasma
metabonomic proﬁles, characterized by cisplatin-induced
hyperglycaemia and elevated creatinine, which were partially
normalized by CBG. The cisplatin-induced metabolic pheno-
type was further characterized by decreased levels of the
BCAAs leucine, isoleucine, and valine and elevated
3-hydroxybutyrate, all of which were normalized by CBG.
While beyond the scope of the present study, the extent to
which normalization of these metabolites merely reﬂects at-
tenuation of anorexia, and the functional consequences of
their normalization in the context of muscle homeostasis
(and tumour cell metabolism), warrants further investigation.
At the molecular level, inhibition of Akt/mTOR-mediated
muscle protein synthesis is a well-established hallmark of both
cancer—and chemotherapy-induced cachexia.52,53 In the
present study, a clear cisplatin-induced suppression of Akt ac-
tivation was observed, as determined by its lower phosphory-
lation at serine 473 and threonine 308 residues. This effect
was particularly apparent from the six-fold decrease in the
phosphorylation ratio of ribosomal protein S6, the down-
stream target of Akt that controls transcriptional initiation of
muscle protein synthesis. CBG treatment resulted in a robust
reversal of the inhibition of Akt/S6-mediated protein synthe-
sis, indicating that at least part of its beneﬁcial effect against
muscle ﬁbre atrophy was due to rescue of the anabolic com-
ponent of muscle homeostasis. CBG also exhibited beneﬁcial
effects against hyperactivated muscle catabolism, via a nor-
malizing effect on dysregulated autophagic ﬂux, a target with
emerging importance in cachexia.43,54,55 Cisplatin increased
the density of p62 puncta (intracellular receptors that target
proteins and organelles for autophagic degradation), accumu-
lation of which is indicative of dysregulated formation and
turnover of autophagosomes. Consistent with this dysregula-
tion, synthesis of both the LC3 autophagosome membrane
component and the p62 proteins was decreased by cisplatin,
further supporting a pathological suppression of effective
turnover. CBG treatment reversed the effects of cisplatin on
LC3 and p62 expression and p62 puncta density, indicative of
a rescue of normal homeostatic autophagy function, which is
necessary to prevent pathological muscle catabolism.56
Upstream pathological processes that drive chemotherapy-
induced alterations in muscle anabolism and catabolism
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are less clear but have been suggested to involve NFκB signal-
ling.6 However, a recent study has demonstrated the critical
role of GC signalling, as chemotherapy-induced cachexia
was abolished in transgenic mice lacking muscle GC recep-
tors.5,51 That study demonstrated that cyclophosphamide-
doxorubicin-5-ﬂuorouracil chemotherapy elicited rapid
systemic inﬂammation (within 4 h), leading to HPA axis
activation and subsequent elevation in systemic corticoste-
rone levels. Consistent with this mechanism, corticosterone
levels were elevated 72 h after cisplatin administration in
the present study; however, it is interesting to note that this
was not modulated by CBG treatment. These data therefore
suggest that CBG likely exerts its protective effects down-
stream of muscle GC receptors, via action on some compo-
nent of the intracellular signal transduction pathways that
mediate GC-induced muscle atrophy. A plausible candidate
is PGC-1α, the PPARγ nuclear hormone receptor coactivator
1α, which has been shown to control autophagy and protein
synthesis processes selectively in glycolytic MHC IIx/b
ﬁbres,40,41,57 which exhibited selective atrophy here. Given
that CBG has recently been identiﬁed as a moderately potent
agonist of PPARγ,27,58 and synthetic PPARγ agonists have
shown efﬁcacy against cachectic weight loss,59 substantiation
of this putative mechanism would be of considerable value.
While a PPARγ-mediated mechanism for the protective ef-
fect of CBG on muscle homeostasis has been posited here,
phytocannabinoids typically have pleiotropic pharmacological
activities, and indeed, CBG has a number of identiﬁed activi-
ties, including modulation of endocannabinoid system com-
ponents.28 Both the canonical endocannabinoids, and an
increasing number of endocannabinoid-like signalling lipids,
have established modulatory roles in many physiological pro-
cesses involved in metabolism and dysregulated in ca-
chexia.49,50,60 We thus performed what is, to the best of
our knowledge, the ﬁrst comprehensive lipidomic analysis of
this class of lipids in hypothalamic and plasma samples from
cachectic animals. Due to limitations in the number of
lipidomic analyses feasible in the present study, we chose
to focus on the hypothalamus, being the primary brain region
involved in metabolic homeostasis, and for which there exists
a considerable body of evidence for neuromodulatory roles
by endocannabinoids in the physiology and pathophysiology
of feeding.28 However, further lipidomic studies would be of
interest in brain regions containing nausea and anorexia
circuits activated by cisplatin, particularly the nucleus of the
solitary tract, lateral parabrachial nucleus, and central amyg-
dala.49 In hypothalami, cisplatin administration elicited
extensive alterations to levels of lipoamines in 11 amide-
conjugate subfamilies, including a profound suppression of
all ethanolamine-conjugated lipoamines (NAEs, which include
anandamide). These observations bear considerable similarity
to the recently characterized brain lipidome of a NAPE-PLD
KO mouse,38 suggesting that cisplatin may have an inhibitory
effect on the predominant biosynthetic enzyme for NAEs.
While the lipidome of other brain regions was not investi-
gated in the present study, broadly consistent reductions in
NAE levels were observed across eight major regions in the
NAPE-PLD KO mouse, indicating that cisplatin’s effects may
not be restricted to the hypothalamus. Consistent with this
possibility, cisplatin also decreased plasma levels of NAEs,
the only screened subfamily for which a decrease was ob-
served in this compartment. Given the diverse central and pe-
ripheral roles of anandamide, oleoylethanolamide and
palmitoylethanolamide in modulating appetite and metabolic
processes,49,61 this observation provides evidence for hith-
erto unrecognized mechanisms by which cisplatin may exert
many of its cachectic effects. Furthermore, if cisplatin does
have a similar effect on NAEs as NAPE-PLD KO, which de-
creased levels in hippocampus, cortex, and striatum, this
raises the intriguing possibility that such a mechanism may
be involved in the phenomenon of chemotherapy-induced
cognitive impairment, also known as ‘chemo brain’.62 Surpris-
ingly, CBG treatment was not associated with any normaliza-
tion of cisplatin’s effects on NAE levels, which could be
considered consistent with the relatively modest effects on
cisplatin-induced anorexia. However, given that the lipodomic
proﬁle was only determined at a single timepoint, an NAE-
mediated mechanism for CBG in this model cannot be ruled
out. In contrast, arguably the most salient feature of the
lipidomic characterization of this model is the observation
that plasma levels of all but one of the N-acyl glycine subfam-
ily of lipoamines were elevated by cisplatin and reversed by
CBG. The association between the anti-cachectic effect of
CBG and systemic N-acyl glycines was further supported by
the signiﬁcant negative correlations between these
lipoamines and EDL muscle mass in animals treated with
CBG. Given the recently emerging evidence for the role of this
lipoamine subfamily in modulating inﬂammation, adipogene-
sis, insulin release, and several GPR18-mediated metabolic
processes,63–66 their functional involvement in the therapeu-
tic effects of CBG, and potential as biomarkers for such ana-
bolic interventions, warrants urgent investigation.
A very limited number of pre-clinical studies have
attempted to investigate the pathophysiology of
chemotherapy-induced cachexia, and the efﬁcacy of anti-
cachectic interventions, in tumour-bearing models.8,67,68
However, the number of experimental groups necessitated
by this approach limits the power of such designed studies
to investigate the chemotherapy-induced cachectic pheno-
type in detail. The present study was speciﬁcally designed
to overcome such limitations, and the inherent impossibility
of administering chemotherapy agents to cancer-naïve hu-
man subjects, such that it had the power to provide a com-
prehensive multi-omic characterization of cisplatin-induced
cachexia, and assess the efﬁcacy of CBG at multiple doses.
The dose of cisplatin used induced a level of weight loss
and anorexia highly consistent with previous reports and
was intended to replicate a typical cycle of cisplatin
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chemotherapy in humans that results in a similarly mild but
signiﬁcant loss of bodyweight,7,22,32–34 rather than high
and/or prolonged dosing regimens that elicit a magnitude of
weight loss (≥20%) that would not be tolerated clinically.4,65
Similarly, the two doses of CBG were chosen based on our
previous studies in cisplatin-naïve animals, which were well
tolerated and elicited a modest but signiﬁcant hyperphagia,
which were thus considered translationally appropriate. Due
to the modest effects of CBG administration in cisplatin-naïve
animals in pilot studies (Supporting Information, Figure S1),
the use of considerable analytical resources for the inclusion
of such groups in the main experimental design was not con-
sidered justiﬁed. Similarly, having determined that the lower
dose of CBG had limited, if any, protective effects against
cisplatin-induced weight loss or anorexia, follow-up ex vivo
mechanistic analyses of samples from this group was consid-
ered unnecessary. While investigation of pharmacokinetic pa-
rameters was beyond the scope of the present study,
previously reported plasma and brain half-lives for CBG of
100 and 96 min,28 suggest that CBG may not have reached
steady-state before the onset of cisplatin’s cachectic effects.
Further studies may thus be warranted to determine whether
prophylactic doses of CBG given at an earlier timepoint (rela-
tive to cisplatin) elicit a greater anti-cachectic effect.
Given that many components of chemotherapy-induced
cachectic pathophysiology attenuated by CBG are common
to cancer-induced cachexia and that CBG has recently been
shown to inhibit colon carcinogenesis and cancer progres-
sion in vivo,69 it will be of great interest to investigate
CBG as an adjunct treatment in tumour-bearing animals re-
ceiving cisplatin treatment. Given that the doses of CBG uti-
lized in the present study exceed levels typically ingested
from medicinal (or recreational) C. sativa use, phase I safety
trials in humans of puriﬁed CBG would be required for pro-
gression of this treatment, should the anti-cachectic efﬁcacy
of CBG be demonstrated in pre-clinical cancer models.
Demonstration of efﬁcacy in pre-clinical tumour studies,
and safety in human trials, is particularly pressing for such
a compound, given the increasingly widespread interest
and use of C. sativa-based treatments (particularly for on-
cology indications) outside of the clinical setting, as a result
of relaxation of legal restrictions in the USA and other
countries.
The data reported here reveal a number of novel aspects
of chemotherapy-induced cachexia pathophysiology, particu-
larly regarding the involvement of endocannabinoid-like
signalling lipids, which may provide novel targets for thera-
peutic interventions against the metabolic and cognitive side
effects of chemotherapy. As a non-psychoactive phytocan-
nabinoid that robustly attenuates chemotherapy-induced
muscle atrophy, CBG may represent a valuable adjunct treat-
ment with signiﬁcant implications for the treatment efﬁcacy,
quality of life, and mortality of the many patients receiving
cisplatin treatment.
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